Last reviewed · How we verify
NCT02789878
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Phase 2 trial testing Goserelin in Prostate Cancer in 64 participants. Completed in 1 August 2022.
30 April 2022
Quick facts
| Lead sponsor | Instituto do Cancer do Estado de São Paulo |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 24 January 2019 |
| Primary completion | 30 April 2022 |
| Estimated completion | 1 August 2022 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Goserelin (goserelin) — full drug profile →
- Prednisone (prednisone) — full drug profile →
- Abiraterone (ABIRATERONE) — full drug profile →
- Apalutamide (apalutamide) — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Instituto do Cancer do Estado de São Paulo — full company profile →
Who can join
Adults 18 to 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen deprivation therapy with goserelin and abiraterone with or without apalutamide prior to radical prostatectomy for patients diagnosed with localized high-risk prostate cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research.
Laccetti AL, Morris MJ, Kantoff PW. · · 2020 · cited 8× · PMID 33402834 · DOI 10.2147/ott.s242921 -
Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.
Yanagisawa T, Rajwa P, Quhal F, Kawada T, et al · · 2023 · cited 7× · PMID 37109028 · DOI 10.3390/jpm13040641 -
Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer.
Gómez Rivas J, Ortega Polledo LE, De La Parra Sánchez I, Gutiérrez Hidalgo B, et al · · 2024 · cited 4× · PMID 39796728 · DOI 10.3390/cancers17010099 -
Very high-risk prostate cancer: multimodality treatment will be the new frontier.
Campobasso D, Prati G, Frattini A. · · 2017 · PMID 29104799 · DOI 10.5173/ceju.2017.1535
Verify or expand the search:
- PubMed search for NCT02789878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Goserelin
Trials testing the same drug.
- NCT07158021 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial · Phase 2 · recruiting
- NCT06348134 — Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surge · Phase 2 · recruiting
- NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
- NCT05827081 — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer · Phase 3 · recruiting
- NCT05870579 — [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast · Phase 1 · recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Instituto do Cancer do Estado de São Paulo trials
Trials by the same sponsor.
- NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
- NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
- NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
- NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
- NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02789878 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
- Last refreshed: 15 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02789878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing